Wednesday, 16 August 2017

Generics News

  • Gilead allows sublicense of HIV drug to generic firms

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 25 Jul, 2014

    Singapore: HIV drug developer, Gilead Sciences has partnered with Medicines Patent Pool (MPP) to expand access to Gilead's investigational drug tenofovir alafenamide (TAF) for HIV and hepat...Read more

  • Bayer plea for stay on compulsory license dismissed

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 17 Sep, 2012

    Bangalore: The Intellectual Property Appellate Board in Chennai, India, has rejected pharma major Bayer's petition seeking a stay on compulsory license to Hyderabad-based Natco Pharma for s...Read more

  • Perrigo rejects Mylan's acquisition bid

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 28 Apr, 2015

    Singapore: Irish firm, Perrigo, has declined the acquisition offer from Mylan revalued at USD60 per share in cash and 2.2 Mylan ordinary shares for each ordinary Perrigo share. The Board p...Read more

  • Ranbaxy, Lundbeck face EU fury for blocking generics

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 04 Jun, 2013

    Singapore: The European Commission (EC) is going to fine seven generic drug firms, including India-based Ranbaxy and Denmark-based Lundbeck, for limiting the supply of cheaper medicines to ...Read more

  • FDA flags GMP issues at Impax's Taiwan facility

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 31 Jul, 2014

    Singapore: Regulatory hurdles continue to haunt Impax Laboratories and its experimental drug, Rytary, that treats idiopathic Parkinson's disease. After facing a tough time with the FDA at t...Read more

  • Lupin gets FDA nod to make generic insomnia drug

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 20 Sep, 2013

    Singapore: The US FDA provided its final approval to Indian drug maker Lupin to manufacture and market a generic version of Sanofi Aventis' Ambien CR extended release tablets. Zolpidem Tar...Read more

  • Aurobindo Pharma files ANDA for HIV generic drug

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 27 May, 2015

    Singapore: India's Aurobindo Pharma has submitted an Abbreviated New Drug Application (ANDA) for dolutegravir 50mg, for tentative approval to the Food and Drug Administration (FDA), for the...Read more

  • Canadian generic maker enters Korea with JV

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 03 Jan, 2013

    Singapore: Montreal-based generic drug developer and marketer Pharmascience is venturing into Korea by forming a joint venture (JV) with Seoul-based Korea Kolmar Holdings. Pharmascience pla...Read more

  • Orexigen, Takeda file lawsuit against Actavis for patent infringement

    Generics |  Regulatory | By BioSpectrum Bureau | 0 Comment | 08 Jun, 2015

    Singapore: Orexigen Therapeutics and Takeda Pharmaceuticals have filed a lawsuit in US against Actavis for filing an abbreviated new drug application (ANDA) to market and sell generic versi...Read more

  • FDA warns Tianjin Zhongan for cGMP lapses

    Generics |  Regulatory | By BioSpectrum Bureau | 0 Comment | 26 Jun, 2014

    Singapore: TheĀ US Food and Drug Administration (FDA) has slapped a warning letter to China based Tianjin Zhongan Pharmaceutical company for manufacturing adulterated active pharmaceutical ...Read more

  • Beximco pharma receives TFDA approval

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 04 Jul, 2014

    Singapore: Beximco pharmaceuticals, a Bangladeshi pharma giant announced that it had received Good Manufacturing Practices approval from the Taiwan Food and Drug Administration (TFDA). The ...Read more

  • Teva to acquire migraine drug firm at $825 mn

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 04 Jun, 2014

    Singapore: With the strategy to strengthen its pain management portfolio, global biopharmaceutical company, Teva Pharmaceutical, is set to acquire biotechnology company focused on treatment...Read more

  • Mayne Pharma appoints a new vice president

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 18 Jun, 2014

    Singapore: Australian drug maker Mayne Pharma announced Mr Blake Cullen as the new vice president of business development, for its US generic products division. The company spokesperson sa...Read more

  • GSK seeks FIPB nod to hike stake in India

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 06 Jan, 2014

    Singapore: British drugmaker GlaxoSmithKline has approached the Foreign Investment Promotion Board (FIPB) to hike stake in its domestic arm by buying 24.33 percent for an estimated Rs 6,400...Read more

  • Pharma FDI cap, right move for India

    Generics |  Opinion | By Nandita Singh | 0 Comment | 31 Jul, 2012

    India's pharma industry, mainly comprising generics has got a breather. The government in India has decided to cap brownfield foreign direct investment in pharma at 49 percent, allaying fea...Read more

  • GSK CEO: London HQ 'knew nothing' of the fraud

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 25 Jul, 2013

    Singapore: Addressing the global media for the first time after allegations were leveled out against Britain's largest drugmaker, GlaxoSmithKline, the company's CEO Sir (Dr) Andrew Witty ha...Read more

  • FDA nod for Lupin's angina generic Ranolazine

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 05 Aug, 2013

    Mumbai: Lupin Phamaceuticals has received final approval for its Ranolazine extended-release tablets, 500 mg and 1000 mg from the US FDA. Lupin's Ranolazine extended-release tablets are th...Read more

  • Eli Lilly files $500 mn suit against Canada govt

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 16 Sep, 2013

    Singapore: Eli Lilly has filed a $500 million international lawsuit against the Canadian government alleging that the country's courts unfairly threw out these patents when challenged by ge...Read more

Survey Box

Does Asia have more to offer to the global 3D cell culture market?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls